anti-cd38

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

Anti-Mouse CD38 Antibody (NIMR5) is an IgG2a, κ inhibitor antibody derived from rats, designed to target and inhibit mouse CD38.

Anti-Human-CD38 Antibody (Daratumumab hexabody) is an antibody. Its expression system is HEK293 cells, and the isotype control is IgG1, Kappa.

Modakafusp alfa (TAK-573) is a humanized anti-CD38 IgG4 monoclonal antibody fused with 2 attenuated IFNα2b molecules, being researched for potential use in treating multiple myeloma [1].

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.